The nature of addiction is often debated along moral versus biological lines. However,
recent advances in neuroscience offer insights that might help bridge the gap between these …

Alcohol use disorders (AUDs) is one of the leading causes of disease and disability in
almost all European countries. Among the alcohol-related diseases, alcoholic liver disease …

The γ-aminobutyric acidB (GABAB) receptor was first demonstrated on presynaptic terminals
where it serves as an autoreceptor and also as a heteroreceptor to influence transmitter …

Aims: The γ-aminobutyric acid (GABAB) receptor agonist, baclofen, has recently been
shown to reduce alcohol intake in alcohol-preferring rats and alcohol consumption and …

Background: Recent clinical trials and case‐reports indicate that baclofen, a GABAB agonist,
may have efficacy for alcohol dependence. Baclofen has been shown to enhance …

Cannabis use disorder (CUD) commonly occurs and carries a notable economic and
functional burden at both individual and societal levels. While there are no clearly …

Alcoholism is a major public health problem and resembles, in many ways, other chronic
relapsing medical conditions. At least 2 separate dimensions of its symptomatology offer …

The past decade has seen an expansion of research and knowledge on pharmacotherapy
for the treatment of alcohol dependence. The Food and Drug Administration (FDA)-approved …

Recent advances in the fields of genetics, molecular biology, behavioral
neuropharmacology, and brain imaging have dramatically changed our understanding of …

-Aminobutyric acid (GABA) 2 is the main inhibitory neurotransmitter in the central nervous
system. The response to GABA is determined by the activation of plasma membrane …